GenMont Biotech Inc.: Q1 2026 EPS of NT$0.05
NQ Score
0/100
N1 Content Completeness
4
AI Summary (NQ-processed)
GenMont Biotech Inc. reported an EPS of NT$0.05, operating revenue of NT$89 million, and net profit after tax of NT$2 million for Q1 2026. The company, operating in the biotechnology and medical industry, draws attention to its future growth.